6th Jan 2022 14:51
Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Says it entered a partnership with Ashfield Engage to build the commercialisation infrastructure for its inhaled COVID-19 treatment SNG001. Explains that this will initially be in the US pending the completion of pivotal trials and regulatory authorisations. Adds that Ashfield Engage has experience in working with Covid-19.
Current stock price: 199.00 pence
Year-to-date change: down 4.3%
By Abby Amoakuh; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Synairgen